HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
ERK,ROS,p38 MAPK | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | Rho,PKA | 98% | ||||||||||||||||
| ML-9 | ✔ | MLCK,Akt | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | Akt,p38 MAPK | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine[3]. Among combinations of hypertension medications, a β-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an effective combination therapy for hypertension, with distinct and complimentary modes of action[4]. Black triangle In the comparison with amlodipine monotherapy, >70% of olmesartan medoxomil/amlodipine recipients, some requiring upwards dosage adjustment, met BP goals. Peripheral oedema was significantly less common in olmesartan medoxomil/amlodipine 40 mg/10 mg per day than amlodipine monotherapy 10 mg/day recipients[5]. Maximal amlodipine concentrations in mothers ranged from 4.4 to 14.7 ng/mL in plasma, and 6.5 to 19.7 ng/mL in milk (Average milk/plasma ratio: 1.4). RID was 3.4% of the maternal weight-adjusted dose. All plasma concentrations in infants were under the quantitation limit (0.4 ng/mL). Infant exposure to amlodipine in breast milk appears very small, suggesting that amlodipine can be used with little influence on infants during breastfeeding[6]. |
| Concentration | Treated Time | Description | References | |
| Ishikawa cells | 10 μM, 15 μM | 12 h | To evaluate the effect of AM on the apoptosis of Ishikawa cells, the results showed that AM induced cell apoptosis. | Cells. 2022 Oct 8;11(19):3156. |
| Ishikawa cells | 15 μM | 48 h | To evaluate the effect of AM on the proliferation of Ishikawa cells, the results showed that AM inhibited cell proliferation. | Cells. 2022 Oct 8;11(19):3156. |
| Ishikawa cells | 0, 1.25, 5, 10, 12.5, 20, 25, 40, 50 μM | 72 h | To evaluate the effect of AM on the proliferation of Ishikawa cells, the results showed that AM inhibited cell proliferation. | Cells. 2022 Oct 8;11(19):3156. |
| MGC803 cells | 0, 5, 10, 20 µM | 24, 48, 72 h | To evaluate the effect of amlodipine on cell proliferation, results showed that amlodipine inhibited GC cell proliferation in a dose-dependent manner. | Funct Integr Genomics. 2024 Apr 18;24(3):77. |
| HGC27 cells | 0, 5, 10, 20 µM | 24, 48, 72 h | To evaluate the effect of amlodipine on cell proliferation, results showed that amlodipine inhibited GC cell proliferation in a dose-dependent manner. | Funct Integr Genomics. 2024 Apr 18;24(3):77. |
| vascular smooth muscle cells (VSMCs) | 5 μM | 24 h | To investigate the effect of amlodipine on VSMC differentiation, results showed that amlodipine increased the expression of α-SMA, CNN1, and SM-MHC but decreased OPN expression. | Br J Pharmacol. 2019 Jul;176(13):2306-2320. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c nude mice | Subcutaneous transplanted tumor model | Peritoneal injection | 15 mg/kg, 20 mg/kg | Every two days for 14 days | To evaluate the inhibitory effect of AM on tumor growth in vivo, the results showed that AM significantly inhibited tumor growth. | Cells. 2022 Oct 8;11(19):3156. |
| NKG mice | Subcutaneous xenograft model | Oral | 10 mg/kg | Once daily for 28 days | To evaluate the effect of amlodipine on tumor growth in vivo, results showed that amlodipine significantly reduced tumor volume and weight in the SYT4-OE group. | Funct Integr Genomics. 2024 Apr 18;24(3):77. |
| Spontaneously hypertensive rats (SHRs) | Spontaneously hypertensive rat model | Oral | 2 mg/kg | Once daily for 10 weeks | To investigate the effect of amlodipine on blood pressure and vascular function in SHRs, results showed that amlodipine promoted VSMC differentiation by upregulating miR-21 expression. | Br J Pharmacol. 2019 Jul;176(13):2306-2320. |
| Sprague-Dawley rats | Amlodipine-induced shock model | Intravenous injection | 17 mg/kg | Three doses at 5, 30, and 60 minutes | To evaluate the efficacy of methylene blue in an amlodipine-induced shock model. Results showed that the methylene blue group had significantly higher survival time, heart rate, and mean arterial pressure compared to the control group. | Ann Emerg Med. 2015 Apr;65(4):410-5 |
| Rats | High-fat diet-induced non-alcoholic fatty liver disease model | Intraperitoneal injection | 5mg/kg | Twice a week for 12 weeks | Vitamin D supplementation alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota and metabolism. | Front Microbiol. 2023 Feb 2;14:1117644 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.45mL 0.49mL 0.24mL |
12.23mL 2.45mL 1.22mL |
24.46mL 4.89mL 2.45mL |
|
| CAS号 | 88150-42-9 |
| 分子式 | C20H25ClN2O5 |
| 分子量 | 408.88 |
| SMILES Code | O=C(C1=C(COCCN)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2Cl)OCC |
| MDL No. | MFCD00864687 |
| 别名 | Intervask; UK-48340; Pelmec |
| 运输 | 蓝冰 |
| InChI Key | HTIQEAQVCYTUBX-UHFFFAOYSA-N |
| Pubchem ID | 2162 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 30 mg/mL(73.37 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1